Amplified Benefit of Clopidogrel Versus Aspirin in Patients With Diabetes Mellitus


Phase N/A Results

Trial Description

To determine whether clopidogrel compared with aspirin would be particularly efficacious in preventing ischemic events in diabetic patients with atherosclerosis.


Trial Design

Randomized, double-blinded, controlled clinical trial.

Patient Involvement

All patients were randomized to either clopidogrel (1,914) or aspirin (1,952) treatment groups. All analyses were performed on an on-treatment basis, with each patient’s time at risk censored 28 days after early discontinuation of the study drug.


Type Measure Time Frame Safety Issue
Primary Vascular death, all-cause stroke, MI, or rehospitalization for ischemia or bleeding.